Visit us at EHA
Oncopeptides presented clinical results from an ongoing Phase I/II study in patients with relapsed and relapsed refractory multiple myeloma in combination with dexamethasone at the European Hematology Association meeting in Vienna.
Upcoming events
FDA - Oncologic Drugs Advisory Committee (ODAC) Meeting
The US Food and Drug Administration, FDA, has announced a forthcoming public advisory committee meeting of the Oncologic Drugs Advisory Committee (ODAC), on October 28, 2021 concerning Oncopeptides’ product Pepaxto. The information is in line with the FDA safety alert on July 28, where the FDA stated that a public meeting may be hold to discuss the safety findings from the OCEAN study.